A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(4 sites)

United States

Local Institution - 0001, Farmington, Connecticut

New York University School Of Medicine, New York, New York

Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma

Local Institution - 0003, Jackson, Tennessee